Telix Symposium at SNMMI 2021 Virtual Annual Meeting
Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15 June.
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68 generator.
Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.
Cardinal Health and Telix Launch Gallium Awareness Campaign
In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the Myth”.
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL amyloidosis.
First Patient Dosed in Japanese Prostate Cancer Imaging Study
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product, Illuccix®.
Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging
Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.
Telix at ANZSNM Annual Scientific Meeting
Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live and local.
Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses
Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
Telix and Monrol Expand Alliance to Include Lutetium Supply
Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR products.